Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

PRF Technologies Ltd. (PRFX)

NCM · Drug Manufacturers - Specialty & Generic

$1.07-0.02 (-1.83%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$3.3M
P/E (TTM)
EPS
$-7.27
Div Yield
52W Range
$1.04–$17.95
Beta
1.05

Company overview

PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company was formerly known as PainReform Ltd. and changed its name to PRF Technologies Ltd. in January 2026. PRF Technologies Ltd. was incorporated in 2007 and is based in Tel Aviv-Yafo, Israel.

Peers in Drug Manufacturers - Specialty & Generic

All in industry →

Recent press releases

PRF Technologies Ltd. has not issued a press release in this window.

SEC filings

All filings →

PRF Technologies Ltd. has not filed an SEC document in this window.

PRF Technologies Ltd. has no reported insider trades in the last 90 days.

Institutional holders

All holders →

No 13F holdings have been reported for PRF Technologies Ltd. in this window.

People at PRF Technologies Ltd.

All people →

Quarterly financials

Full financials →
Revenue trend
12/24
NI
RevenueNI = Net Income
EPS trend (diluted)
EPS history not available.